Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Want to cut your energy bills? Here’s how five experts are doing it 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
NEW YORK, Feb. 22, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased DaVita Inc. (NYSE:DVA) securities between August 5, 2015 and October 21, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/davita-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.
On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis.
If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/davita-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
